These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25939962)

  • 1. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.
    Nickel RS; Daves M; Keller F
    Pediatr Blood Cancer; 2015 Nov; 62(11):2050-1. PubMed ID: 25939962
    [No Abstract]   [Full Text] [Related]  

  • 2. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.
    Shah NP
    Clin Adv Hematol Oncol; 2011 Dec; 9(12):925-6. PubMed ID: 22252660
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission.
    Andrews C; Lipton J
    Leuk Lymphoma; 2019 Dec; 60(13):3099-3101. PubMed ID: 31556337
    [No Abstract]   [Full Text] [Related]  

  • 4. Ponatinib-induced neutrophilic panniculitis.
    Zhang M; Hassan KM; Musiek A; Rosman IS
    J Cutan Pathol; 2014 Jul; 41(7):597-601. PubMed ID: 24602068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
    Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
    Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
    [No Abstract]   [Full Text] [Related]  

  • 6. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
    Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
    Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
    Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
    Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia.
    Katagiri S; Tauchi T; Okabe S; Minami Y; Kimura S; Maekawa T; Naoe T; Ohyashiki K
    Clin Cancer Res; 2013 Mar; 19(6):1422-32. PubMed ID: 23319824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.
    Sanford D; Kantarjian H; Skinner J; Jabbour E; Cortes J
    Haematologica; 2015 Dec; 100(12):e494-5. PubMed ID: 26341741
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
    Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
    Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia.
    Engel NW; Constantin A; Fowlkes S; Assouline S
    J Oncol Pract; 2016 Jun; 12(6):592-4. PubMed ID: 27246687
    [No Abstract]   [Full Text] [Related]  

  • 12. BCR-ABL1 compound mutations drive ponatinib resistance.
    Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponatinib for chronic myeloid leukemia.
    Goldman JM
    N Engl J Med; 2012 Nov; 367(22):2148-9. PubMed ID: 23190226
    [No Abstract]   [Full Text] [Related]  

  • 14. Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia.
    Tefferi A
    Hematol Oncol; 2018 Oct; 36(4):718-720. PubMed ID: 29901221
    [No Abstract]   [Full Text] [Related]  

  • 15. [Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?].
    Thomas X
    Bull Cancer; 2011 Jul; 98(7):761-7. PubMed ID: 21700550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutations.
    He Y; Zheng J; Hu Y; Xiao H; Liu J; Li X; Du W; Chen X; Hu Y; Huang S
    Eur J Haematol; 2010 Jan; 84(1):87-8. PubMed ID: 19744127
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.
    Curik N; Laznicka A; Polivkova V; Krizkova J; Pokorna E; Semerak P; Suchankova P; Burda P; Hochhaus A; Machova Polakova K
    Leukemia; 2024 Jun; 38(6):1415-1418. PubMed ID: 38615117
    [No Abstract]   [Full Text] [Related]  

  • 19. Ponatinib in the therapy of chronic myeloid leukemia.
    Poch Martell M; Sibai H; Deotare U; Lipton JH
    Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.